Pathogenesis of Nonalcoholic Fatty Liver Disease and Development of New Therapeutic Drugs
YU Wenxue, SUN Yuxin, JIN Lili, WANG Qiuyu*
NAFLD (nonalcoholic fatty liver disease) is a common chronic fatty liver disease. With the development of the disease, it can also cause type 2 diabetes, cardiovascular disease and so on. At present, the common treatments include lipid-lowering drugs, peroxisome growth factor activating receptor agonists, liver-protecting antiinflammatory drugs, etc. But there is a lack of specific drugs for NAFLD. It is found that the pathogenesis of NAFLD is closely related to insulin resistance by researches. Antibacterial peptides promoting insulin can alleviate insulin resistance and treat NAFLD. This article reviews the pathogenesis of NAFLD and researches of therapeutic drugs. Combined with the researches of the author’s laboratory, the advantages of insulin-promoting antibacterial peptides in the treatment of NAFLD are analzed.
CN
EN